RARE ULTRAGENYX PHARMACEUTICAL IN revenue, earnings and financials

For the quarter ended June 30, 2026, ULTRAGENYX PHARMACEUTICAL IN reported revenue of $214M (up 28.1% from a year earlier), net income of −$92.0M and diluted EPS of −$0.90; over the last four quarters revenue was $717M and net income −$586M; for the fiscal year ended December 2025 revenue was $673M, up 20.2% on the year before.

RARE annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $673M, gross profit n/a, operating income −$535M, net income −$575M (margin -85.4%), EPS −$5.83
• Fiscal year ended Dec 2024: revenue $560M, gross profit n/a, operating income −$536M, net income −$569M (margin -101.6%), EPS −$6.29
• Fiscal year ended Dec 2023: revenue $434M, gross profit n/a, operating income −$569M, net income −$607M (margin -139.9%), EPS −$8.25
• Fiscal year ended Dec 2022: revenue $363M, gross profit n/a, operating income −$649M, net income −$707M (margin -194.7%), EPS −$10.12
• Fiscal year ended Dec 2021: revenue $351M, gross profit n/a, operating income −$382M, net income −$454M (margin -129.2%), EPS −$6.70

RARE quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $214M (up 28.1% year over year), net income −$92.0M, EPS −$0.90
• Quarter ended Mar 31, 2026: revenue $136M (down 2.2% year over year), net income −$185M, EPS −$1.84
• Quarter ended Dec 31, 2025 (from the annual report): revenue $207M (up 25.8% year over year), net income −$129M, EPS −$1.28
• Quarter ended Sep 30, 2025: revenue $160M (up 14.7% year over year), net income −$180M, EPS −$1.81
• Quarter ended Jun 30, 2025: revenue $167M (up 13.6% year over year), net income −$115M, EPS −$1.17
• Quarter ended Mar 31, 2025: revenue $139M (up 27.7% year over year), net income −$151M, EPS −$1.57
• Quarter ended Dec 31, 2024 (from the annual report): revenue $165M (up 29.5% year over year), net income −$133M, EPS −$1.34
• Quarter ended Sep 30, 2024: revenue $139M (up 42.3% year over year), net income −$134M, EPS −$1.40
• Quarter ended Jun 30, 2024: revenue $147M (up 35.7% year over year), net income −$132M, EPS −$1.52
• Quarter ended Mar 31, 2024: revenue $109M (up 8.3% year over year), net income −$171M, EPS −$2.03
• Quarter ended Dec 31, 2023 (from the annual report): revenue $127M (up 23.0% year over year), net income −$124M, EPS −$1.44
• Quarter ended Sep 30, 2023: revenue $98.1M (up 8.1% year over year), net income −$160M, EPS −$2.23
• Quarter ended Jun 30, 2023: revenue $108M (up 21.2% year over year), net income −$160M, EPS −$2.25
• Quarter ended Mar 31, 2023: revenue $100M (up 25.7% year over year), net income −$164M, EPS −$2.33
• Quarter ended Dec 31, 2022 (from the annual report): revenue $103M (up 23.9% year over year), net income −$152M, EPS −$2.17
• Quarter ended Sep 30, 2022: revenue $90.7M (up 11.1% year over year), net income −$245M, EPS −$3.50
• Quarter ended Jun 30, 2022: revenue $89.3M (up 2.7% year over year), net income −$158M, EPS −$2.26
• Quarter ended Mar 31, 2022: revenue $79.9M (down 19.6% year over year), net income −$152M, EPS −$2.19
• Quarter ended Dec 31, 2021 (from the annual report): revenue $83.4M, net income −$122M, EPS −$1.78
• Quarter ended Sep 30, 2021: revenue $81.6M, net income −$73.0M, EPS −$1.08

RARE cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$466M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$414M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$475M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$380M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$339M, share buybacks n/a

RARE balance sheet

• Jun 30, 2026: cash $125M, total assets $1.26B, total liabilities $1.55B, shareholders' equity −$291M
• Mar 31, 2026: cash $175M, total assets $1.30B, total liabilities $1.53B, shareholders' equity −$236M
• Dec 31, 2025: cash $421M, total assets $1.53B, total liabilities $1.61B, shareholders' equity −$80.0M
• Sep 30, 2025: cash $203M, total assets $1.19B, total liabilities $1.17B, shareholders' equity $9.16M
• Jun 30, 2025: cash $176M, total assets $1.31B, total liabilities $1.15B, shareholders' equity $151M
• Mar 31, 2025: cash $127M, total assets $1.31B, total liabilities $1.16B, shareholders' equity $144M
• Dec 31, 2024: cash $174M, total assets $1.50B, total liabilities $1.24B, shareholders' equity $255M
• Sep 30, 2024: cash $151M, total assets $1.54B, total liabilities $1.18B, shareholders' equity $347M

What is RARE's revenue?

ULTRAGENYX PHARMACEUTICAL IN reported $717M of revenue over its last four quarters, through June 30, 2026.

Is RARE profitable?

No. ULTRAGENYX PHARMACEUTICAL IN lost $586M over the last four quarters.

What is RARE's EPS?

Diluted earnings per share over the last four quarters were −$5.83; −$0.90 in the latest quarter.

RARE ownership and insider trades · All stocks